Firma Chun Cheong
Concise Prescribing Info
Neovascular (wet) age-related macular degeneration (AMD); visual impairment due to macular oedema secondary to retinal vein occlusion (branch or central RVO); visual impairment due to diabetic macular oedema (DME); visual impairment due to myopic choroidal neovascularisation (myopic CNV).
Dosage/Direction for Use
Intravitreal inj Adult Wet AMD 2 mg (50 microlitres). Initially 1 inj mthly for 3 consecutive doses, then extend treatment interval to 2 mth. Based on physician's judgment, treatment interval maybe further extended using a treat-&-extend dosing regimen, increasing inj intervals in 2- or 4-wkly increments to maintain stable visual &/or anatomic outcomes. Macular oedema secondary to RVO (branch or central RVO) 2 mg (50 microlitres). After initial inj, treatment is given mthly. Interval between 2 doses should not be shorter than 1 mth. DME 2 mg (50 microlitres). Intially 1 inj mthly for 5 consecutive doses, followed by 1 inj every 2 mth. Myopic CNV Single 2 mg (50 microlitres) inj. Additional doses may be given if visual &/or anatomic outcomes indicate that the disease persists. Interval between 2 doses should not be shorter than 1 mth.
Hypersensitivity. Active or suspected ocular or periocular infection. Active severe intraocular inflammation.
Special Precautions
Endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear & iatrogenic traumatic cataract. Do not inj while IOP is ≥30 mmHg. Potential for immunogenicity. Reports of non-ocular haemmorhage & arterial thromboembolic events. Patients w/ history of stroke or transient ischaemic attacks or MI w/in the last 6 mth. Increased risk of systemic adverse events w/ bilateral treatment. Patients w/ risk factors for retinal pigment epithelial tears. Withhold treatment in cases of rhegmatogenous retinal detachment or stage 3 or 4 macular holes; retinal break; decreased best-corrected visual acuity (BCVA) of ≥30 letters compared w/ the last assessment of visual acuity; subretinal haemorrhage involving the centre of fovea, or if the size of haemorrhage is ≥50% of total lesion area. Withhold dose w/in the previous or next 28 days in the event of a performed or planned intraocular surgery. Not recommended in patients w/ clinical signs of irreversible ischaemic visual function loss. Concomitant use w/ other anti-VEGF. Minor influence on the ability to drive & use machines. Women of childbearing potential should use effective contraception during treatment & for at least 3 mth after last inj. Pregnancy. Not recommended during breastfeeding.
Adverse Reactions
Conjunctival haemorrhage, reduced visual acuity, eye pain. Cataract, IOP increased, vitreous detachment, vitreous floaters, retinal pigment epithelial tear, detachment of retinal pigment epithelium, retinal degeneration, vitreous haemorrhage, cataract cortical, cataract nuclear, cataract subcapsular, corneal erosion, corneal abrasion, blurred vision, inj site pain, foreign body sensation in eyes, increased lacrimation, eyelid oedema, inj site haemorrhage, punctate keratitis, conjunctival & ocular hyperaemia.
ATC Classification
S01LA05 - aflibercept ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.
Eylea soln for intravitreal inj 40 mg/mL
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in